Educational information only. Not medical advice. Talk to a qualified healthcare professional before using any compound. Disclaimer

Longevity & Anti-aging

SS-31

Also known as Elamipretide, Bendavia, MTP-131, Forzinity (brand)

Moderate human evidenceApproved medicineWADA prohibited

Price range: €35 through €77

Discussed for: Mitochondrial energy, muscle and heart function.

Sequence: not listed. Modified or non-standard residues are left out on purpose.

Effect strengthHow hard it acts on the body4/10
Proof levelHow well that is shown in humans6/10
Risk levelHow much can go wrong2/10

Editorial 1 to 10 estimates from published research, not measured values. How to read these

Save to wishlist
Save to wishlist

01 / Identity

What it is

SS-31 is a synthetic tetrapeptide. Main reported uses: mitochondrial energy, muscle and heart function. Current status: FDA accelerated approval (2025) for Barth syndrome only; anti-aging use is off-label.

Molecule type
Synthetic tetrapeptide
How it is taken
Injection (SC)
Other names
Elamipretide, Bendavia, MTP-131, Forzinity (brand)

Route only. This library does not publish doses or protocols.

02 / Mechanism

How it is thought to work

Binds cardiolipin in mitochondrial membranes, improving energy production and reducing oxidative stress

03 / Potential benefits

What people use it for

Mitochondrial energy, muscle and heart function

Moderate human evidence

Some human trials exist, but they are smaller, shorter or mixed.

Listed uses are what people use it for, not proven outcomes.

04 / Known risks

Side effects and risks

Injection-site reactions (common), headache

Risk level 2 of 10

Lower risk score: reported side effects are mostly mild. Low risk is not no risk, especially for unregulated products.

Unknown long-term effects count as a risk, not as a clean record.

05 / Regulatory

Regulatory status

Status
Approved medicine
Details
FDA accelerated approval (2025) for Barth syndrome only; anti-aging use is off-label
Sport (WADA)
Yes: S0 (unapproved substance) when not prescribed

Status reflects information up to mid-2026 and changes over time. Check current sources.

06 / Evidence quality

How good is the evidence?

Moderate: human clinical trials

How we grade evidence

07 / Notes and sources

Notes and sources

  • Anyone using compounds like this regularly should have medical supervision and bloodwork (for example IGF-1, glucose and HbA1c, hormones, lipids).
  • Source: Peptide Reference Table, an editorial review of published research up to mid-2026. Scores are 1 to 10 editorial estimates, not measured values. Regulatory and WADA status change over time.

Educational information only. Not medical advice. Talk to a qualified healthcare professional before using any compound.